

July 20, 2016

To: SHC and LPCH Medical Staff

From: Stanford Healthcare Clinical Laboratory

Subject: Improving celiac disease serology tests at Stanford Clinical Laboratory

The Clinical Chemistry and Immunology (Hillview) section of the Stanford Healthcare Clinical Laboratory will implement new celiac disease serology tests to improve pediatric and adult patient care.

The new tests are performed on Thermo Fisher Phadia platform, starting on **July 27, 2016**. These tests are new generation fluoroenzymeimmunoassays, with increased specificity/sensitivity and extended measuring ranges.

New reporting ranges and cutoff values:

IgA anti-TTG:	1 – 128 U/mL	(positive result ≥ 8 U/mL)
IgG anti-DGP:	1 – 300 U/mL	(positive result ≥ 8 U/mL)
IgA anti-DGP:	1 – 140 U/mL	(positive result ≥ 8 U/mL)
IgG anti-TTG (new):	1 – 600 U/mL	(positive result ≥ 8 U/mL)

Test order codes remain unchanged, with addition of LABGTTG:

LABATTG:	IgA anti-tissue transglutaminase antibodies
LABGDGP:	IgG anti-deamidated gliadin antibodies
LABYDGIGA:	IgA anti-deamidated gliadin antibodies
LABGTTG:	IgG anti-tissue transglutaminase antibodies

Test order code remains unchanged for the updated celiac disease screen panel:

LABCDAS:	IgA anti-tissue transglutaminase antibodies
	IgG anti-deamidated gliadin antibodies
	Total IgA level

Please contact Run Zhang Shi, PhD, Assistant Director of Clinical Chemistry and Immunology, at 650-725-2080, and/or Customer Service at 1-877-717-3733 with any questions or comments.